Reveals the Greek at the United Cup, "I got really scared after my US Open loss with my back, because I just couldn't walk for two days." ...

Recent 2025 studies at Agios Vasileios reveal Linear B tablets documenting trade and rituals, alongside luxury artifacts ...

On December 27 the Greek Orthodox Church celebrates the Feast Day of Agios Stefanos. Saint Stephen was the first of the seven ...

CAMBRIDGE - The U.S. Food and Drug Administration (FDA) has not issued a decision on Agios Pharmaceuticals’ (NASDAQ:AGIO) supplemental New Drug Application (sNDA) for mitapivat by its expected ...

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

Agios Pharmaceuticals, Inc. stock plunged 49% after mixed Phase 3 results for mitapivat in Sickle Cell Disease, raising doubts about future approvals. Mitapivat met the primary hemoglobin endpoint but ...

Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026. Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% ...

Nov 19 (Reuters) - Agios Pharmaceuticals (AGIO.O), opens new tab said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but ...

Shares of Agios Pharmaceuticals (AGIO) plunged ~45% in the premarket on Wednesday after the biotech announced a mixed outcome from a late-stage trial for its lead asset mitapivat in sickle cell ...

While mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance. 40.6% of ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...